title: [The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II].
abstract: The studies results of statin influence on hemostasis are various. The aim of our study was to evaluate the effects of simvastatin and atorvastatin on hemostatic parameters, such as activity of factor X, antithrombin III, fibrinogen concentration and Lp(a). 72 patients (pts) aged 40-65 were involved in the study; 49 of them suffered from hyperlipidemia II (hlp II) with the initial concentration of total cholesterol (TC) >200 mg/dL, cholesterol LDL (LDL-C) >145 mg/dL, triglycerides (TG) <400 mg/dL. The control group consisted of 20 healthy persons. The pts with hlp II who underwent 4 weeks long lipid lowering diet were randomized into two groups: I--27 pts treated with simvastatin (20 mg/d), II--22 pts treated with atorvastatin (10 mg/d). The active statin therapy lasted 8 weeks. The activity of factor X and antithrombin III (AT III) was estimated by amidolytic methods, fibrinogen concentration (Fb) by the Clauss method, Lp(a)-immunoenzymatic method. The mean values of factor X activity and Fb serum concentration were higher in pts with hip II than in the control group, the AT III activity was lower. The Lp(a) concentration didn't differ between groups. Statin treatment was associated with significant reduction of factor X activity. Both simvastatin and atorvastatin markedly increased AT III (87%, 98%) in comparison to the initial values. No changes of Lp(a) concentration were observed during statin therapy. Atorvastatin therapy significantly increased the Fb concentration (12.3%). Simvastatin treatment didn't influence Fb concentration.
authors.affiliation: Zakład Farmakologii i Terapii Monitorowanej z Oddziałem Chorób Wewnetrznych, Katedra Farmakologii i Farmakologii Klinicznej Uniwersytetu Medycznego, Lodzi.
authors.forename: Marlena
authors.initials: M
authors.lastname: Broncel
authors.forename: Iwona
authors.initials: I
authors.lastname: Marczyk
authors.forename: Julita
authors.initials: J
authors.lastname: Chojnowska-Jezierska
authors.forename: Marta
authors.initials: M
authors.lastname: Michalska
authors.forename: Joanna
authors.initials: J
authors.lastname: Sikora
authors.forename: Barbara
authors.initials: B
authors.lastname: Kostka
mesh_terms: D000368:Aged; D000990:Antithrombin III / Q000187:drug effects*; D000069059:Atorvastatin; D005170:Factor X / Q000187:drug effects*; D005260:Female; D005340:Fibrinogen / Q000187:drug effects*; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000494:pharmacology*; D019821:Simvastatin / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000990:Antithrombin III; D005170:Factor X; D005340:Fibrinogen; D000069059:Atorvastatin; D019821:Simvastatin